| A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (NCT05338619) | Sung Yong Lee | 2022-06-30 |
| Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (NCT05089916) | AIO-Studien-gGmbH | 2022-01-20 |
| Osimertinib for Advanced EGFR-positive NSCLC Patients (NCT05037331) | National University Hospital, Singapore | 2021-07-22 |
| A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases (NCT04643847) | First People's Hospital of Hangzhou | 2020-11-30 |
| Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis (NCT07239102) | Beijing Tiantan Hospital | 2020-01-01 |
| Phase 2 Study of Dacomitinib in NSCLC (NCT04027647) | National Cancer Centre, Singapore | 2019-09-11 |
| A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients (NCT04001777) | Ascentage Pharma Group Inc. | 2019-07-04 |
| Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC (NCT04105153) | Thoraxklinik-Heidelberg gGmbH | 2019-04-15 |
| Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients (NCT03382795) | Korea University Guro Hospital | 2018-01-03 |
| First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors (NCT02729298) | Sumitomo Pharma America, Inc. | 2016-12-14 |
| A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) (NCT03126799) | National Cancer Center, Korea | 2016-11-01 |
| A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy (NCT02788058) | First People's Hospital of Hangzhou | 2016-05-01 |
| Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (NCT02125240) | Betta Pharmaceuticals Co., Ltd. | 2014-09-01 |
| Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC (NCT02194556) | Betta Pharmaceuticals Co., Ltd. | 2014-07-01 |
| Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma (NCT02103257) | Betta Pharmaceuticals Co., Ltd. | 2014-03-01 |
| Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma (NCT01665417) | Betta Pharmaceuticals Co., Ltd. | 2012-08-01 |